COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-26-00528 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Antoni Ribas und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of California Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Melanoma, Proto-Oncogene Proteins B-raf. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692 ) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n = 265) for BRAF V600–mutant unresectable or metastatic melanoma failed to reach its primary end point of progression-free survival at 24 months. This final analysis reports overall survival (OS) during at least 5 years of extended follow-up. At the end of the trial (August 21, 2024), the median duration of follow-up was 76.9 months (range, 73.7-83.3 months). The median OS was 61.5 months (95% CI, 41.6 to not evaluable) for the sparta-DabTram arm and 41.6 months (95% CI, 30.6 to 56.9) for the placebo-DabTram arm (hazard ratio, 0.760 [95% CI, 0.598 to 0.966]). The safety findings were consistent with the known safety profile for sparta-DabTram. The most common treatment-related adverse event (TRAE) was pyrexia (65.9% v 46.2%, respectively, in the two study arms). Grade ≥3 TRAEs were reported in 57.3% and 36.7% of patients in the two arms, respectively. The combination of sparta-DabTram appears to improve OS compared with dabrafenib and trametinib alone in patients with BRAF V600–mutant metastatic melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California Los Angeles, Los Angeles, CA.
- Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.
- Université Paris-Saclay, Gustave Roussy, Inserm, Biomarqueurs Prédicteurs et nouvelles Stratégies Moléculaires en Thérapeutique Anticancéreuse, Villejuif, France.
- University Hospital Essen, National Center for Tumor Diseases (NCT-West), German Cancer Consortium, Both Campus Essen, and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
- The Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
- University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Antoni Ribas, Caroline Robert, Dirk Schadendorf, Georgina V Long, Hussein Tawbi, Keith Flaherty, Paolo A Ascierto, Paul Nathan, Piotr Rutkowski, Oleg V Leonov, Paul Lorigan, Sorilla Prey, Maristella Saponara, Daniil Stroyakovskiy, Celeste Lebbe, Michele Maio, Pamela Salman Boghikian, Ralf Gutzmer, Mark Russo, Reinhard Dummer
Zitieren
APA
Ribas, A., Robert, C., Schadendorf, D., Long, G. V., Tawbi, H., Flaherty, K., Ascierto, P. A., Nathan, P., Rutkowski, P., Leonov, O. V., Lorigan, P., Prey, S., Saponara, M., Arance, A., Gaudy-Marqueste, C., Stroyakovskiy, D., Lebbe, C., Maio, M., Del Vecchio, M., …, & Dummer, R. (2026). COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00528
Vancouver
Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, et al. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00528
BibTeX
@article{Ribas2026,
author = {Ribas, Antoni and Robert, Caroline and Schadendorf, Dirk and Long, Georgina V and Tawbi, Hussein and Flaherty, Keith and Ascierto, Paolo A and Nathan, Paul and Rutkowski, Piotr and Leonov, Oleg V and Lorigan, Paul and Prey, Sorilla and Saponara, Maristella and Arance, Ana and Gaudy-Marqueste, Caroline and Stroyakovskiy, Daniil and Lebbe, Celeste and Maio, Michele and Del Vecchio, Michele and Boghikian, Pamela Salman and Gutzmer, Ralf and Depenni, Roberta and Miskic, Marina and Russo, Mark and Dummer, Reinhard},
title = {COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00528}
}
EUVIMED